Developer docs
API playgroundTry for free, no card

Search company profiles

Jumpcode Genomics

Full company profile

uuid000286s

Namestring
Jumpcode Genomics
Legal namestring
Jumpcode Genomics, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Jumpcode Genomics is a privately held life-sciences tools company, founded in 2016 and headquartered in San Diego, California, that develops and sells CRISPR-Cas9 based nucleic-acid depletion reagents branded as DepleteX™ and CRISPRclean™. The company's core technology uses pools of designed guide RNAs to cleave abundant, uninformative sequences — ribosomal RNA, mitochondrial DNA/RNA, globin, high-expressing housekeeping transcripts, and host DNA in microbiome samples — in next-generation sequencing (NGS) libraries prior to sequencing, redistributing read capacity toward biologically relevant molecules. The product portfolio spans core kits (Single Cell RNA Boost, Mitochondrial DNA Depletion, Human DNA Depletion, Stranded Total RNA Prep with rRNA depletion for human/mouse/rat plus 212 bacterial species), add-on panels (Nasopharyngeal Microbial RNA Boost, High Expressing RNA, Globin, Insulin), bulk-format reagents for high-throughput screening, and a Custom Guide RNA Design service. Validated integrations with 10x Genomics, PacBio, BD Rhapsody, Element AVITI, and Parse Evercode platforms position the kits as an upstream depletion step in established single-cell and bulk sequencing workflows.

The company sells primarily through direct sales with quote-based pricing (kit-level price points disclosed at roughly $3,000–$7,680 for catalog SKUs), supplemented by a global distribution network anchored by Revvity and regional partners covering DACH, Japan, Korea, France, and ANZ. Customers span academic and translational research institutions (University of Oxford, University of Verona, Polytechnic University of Marche, TGen) and early commercial users (ImYoo), with no disclosed large-pharma reference accounts. Go-to-market emphasizes scientific publications (Genome Research, Cell Reports Methods, bioRxiv), customer stories, technical webinars, and presence at genomics conferences (PAG, ASHG, ASM Microbe, ABRF). Strategic positioning has expanded beyond research tools into public-health and biodefense applications via the BARDA DRIVe partnership and the €24 million EU4Health grant consortium with Ginkgo Bioworks and TGen.

Jumpcode has raised approximately $23.5 million in total disclosed equity funding, including a $21 million Series B in January 2021 co-led by Baird Capital and Arboretum Ventures with LYZZ Capital. The company operates with 11–50 employees and is led by CEO Yaron Hakak (ex-Illumina, Affymetrix, Arena Pharmaceuticals), CFO Brandon Poe (ex-Illumina, Genome Medical), and Chief Scientist Stanley Nelson (UCLA), with board representation from operating partner Frank Witney (former Affymetrix and Dionex CEO). Revenue is not publicly disclosed, and the company has not announced a Series C or IPO as of 2025.

Short descriptiontext

Jumpcode Genomics develops CRISPR-Cas9 based DepleteX™ and CRISPRclean™ reagent kits that remove uninformative sequences (rRNA, mitochondrial DNA, host DNA) from next-generation sequencing libraries, serving academic, biotech, and public-health researchers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NGS depletion kits, CRISPR-Cas9 reagents, ribodepletion solutions, single cell RNA boost, microbiome sequencing tools
Industry2 codes
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomics Sample Preparation Reagents
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Research Kits and Reagents
TypeOne Time License
Description

Sale of DepleteX™ and CRISPRclean™ reagent kits for NGS library preparation and depletion. Products include single cell RNA boost kits, ribodepletion kits, mitochondrial DNA depletion kits, human DNA depletion kits, and bulk ribodepletion reagents. Revenue generated through direct sales and distributor network.

jumpcodegenomics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1DepleteX™ Human DNA Depletion Kit (KIT2020) - Early Access
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$3,000 per kit (Early Access pricing)

jumpcodegenomics.com
2CRISPRClean™ Bulk Ribodepletion Reagents (Human, Mouse, Rat) - KIT1026
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$7,680 for 1536 samples (96 samples per reaction, 16 reactions)

jumpcodegenomics.com
3CRISPRclean™ Plus Stranded Total RNA Prep - KIT1016
ModelUnit PricingBilling cadencePay-as-you-go
Notes

24 samples per kit - Quote-based pricing

jumpcodegenomics.com
4DepleteX™ Single Cell RNA Boost Kit - KIT1037
ModelUnit PricingBilling cadencePay-as-you-go
Notes

24 samples per kit - Quote-based pricing

jumpcodegenomics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1DepleteX™
Description

Programmable endonuclease technology platform for NGS depletion using CRISPR-Cas9 to remove uninformative sequences.

jumpcodegenomics.com
+1 more record
Core offering1 text field

Jumpcode Genomics develops and sells CRISPR-Cas9 based nucleic acid depletion kits (branded DepleteX™ and CRISPRclean™) that remove abundant, uninformative sequences — such as ribosomal RNA, mitochondrial DNA, globin transcripts, and high-expressing housekeeping genes — from next-generation sequencing (NGS) libraries prior to sequencing. The portfolio includes single cell RNA boost kits, ribodepletion kits, mitochondrial and human DNA depletion kits, tissue-specific RNA depletion panels, bulk ribodepletion reagents, and custom guide RNA design services for life sciences researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • ~50% boost in reads useful for secondary analysis in single cell RNA-seq
+6 more records
Product overview1 text field

Jumpcode Genomics offers a CRISPR-Cas9 based technology platform called DepleteX™ / CRISPRclean™ for removing unwanted sequences from NGS libraries prior to sequencing. The product portfolio consists of: (1) Core depletion kits including DepleteX™ Single Cell RNA Boost Kit (KIT1037), DepleteX™ Mitochondrial DNA Depletion Kit (KIT2002), DepleteX™ Human DNA Depletion Kit (KIT2020), CRISPRclean™ Plus Stranded Total RNA Prep with rRNA Depletion (KIT1016), and CRISPRclean™ Stranded Total RNA Prep with rRNA Depletion (KIT1014); (2) Add-on depletion panels including DepleteX™ Nasopharyngeal Microbial RNA Boost (KIT1039), DepleteX™ High Expressing RNA Depletion Kit (KIT1020), DepleteX™ Globin Depletion Kit (KIT1024), DepleteX™ RNA Depletion Panel/Insulin (KIT1025), and Bulk Ribodepletion Reagents (KIT1026); (3) Custom Guide RNA Design service for customized depletion panels. These products work together as an integrated workflow—core kits provide foundational depletion capabilities while add-on panels offer targeted depletion for specific tissues or applications, all utilizing the patented CRISPR-Cas9 mediated depletion technology to remove abundant uninformative sequences and redistribute sequencing reads to biologically relevant molecules.

Product and service11 records
1DepleteX™ Single Cell RNA Boost Kit
CategorySingle Cell Sequencing Reagents
Description

A CRISPR-Cas9 based kit that removes ribosomal, mitochondrial, non-variable gene fragments, and other uninformative reads before single cell RNA sequencing, redistributing ~50% of sequencing clusters to informative reads. Validated for short and long read sequencing with 10x Genomics, PacBio, and BD Rhapsody platforms; 24 samples per kit.

2DepleteX™ Mitochondrial DNA Depletion Kit
CategoryHuman DNA Depletion Reagents
Description

CRISPR-based depletion kit that removes mitochondrial DNA or RNA from human-derived tissue samples with high mitochondrial content, redirecting sequencing reads to biologically valuable information.

3DepleteX™ Human DNA Depletion Kit
CategoryMicrobiome Depletion Reagents
Description

CRISPR-based depletion kit that removes human DNA from microbiome samples with high human contamination, achieving a 16-fold increase in bacterial reads and unbiased preservation of microbial community composition.

4CRISPRclean™ Plus Stranded Total RNA Prep with rRNA Depletion
CategoryRibodepletion Reagents
Description

Stranded total RNA library prep with integrated ribosomal RNA depletion targeting 200+ bacteria species in addition to human, mouse, and rat rRNA. Achieves >80% depletion of eukaryotic and bacterial rRNA, suitable for complex samples containing mixtures of eukaryotic and bacterial cells; 24 samples per kit.

5CRISPRclean™ Stranded Total RNA Prep with rRNA Depletion (Human, Mouse, Rat)
CategoryRibodepletion Reagents
Description

Specific, unbiased rRNA depletion and library prep for RNA-seq targeting human 5S, 5.8S, 18S, 28S, 45S precursor, and mitochondrial rRNA genes; provides >98% strand specificity and high-quality representation of transcripts.

6DepleteX™ Nasopharyngeal Microbial RNA Boost
CategoryRNA Depletion Panels
Description

Removes abundant human RNA from nasopharyngeal samples to boost discovery of novel microbes and pathogens; enables pathogen detection at Cq values up to 30 with 4 million reads.

7DepleteX™ Rare Transcript Boost Kit (High Expressing RNA Depletion Kit)
CategoryRNA Depletion Panels
Description

Broad RNA depletion panel removing the ~4,450 highest expressing transcripts from poly-A selected RNA-Seq libraries derived from fibroblasts and whole blood, reassigning ~70% of sequencing reads to low-expressing biologically relevant transcripts and providing ~5-fold increased coverage of lower expressing transcripts.

8DepleteX™ Globin Depletion Kit
CategoryRNA Depletion Panels
Description

Removes four highly expressed human globin transcripts (HBA1, HBA2, HBB, HBD) from RNA-seq libraries, achieving >99% depletion and redistributing sequencing clusters to biologically relevant transcripts for maximized UMI and gene sensitivity.

9DepleteX™ Insulin Depletion Kit
CategoryRNA Depletion Panels
Description

Tissue-specific depletion panel removing highest expressing insulin transcripts from pancreatic tissue samples, reassigning sequencing reads to lower expressing transcripts for increased coverage.

10CRISPRclean™ Bulk Ribodepletion Reagents (Human, Mouse, Rat)
CategoryRibodepletion Reagents
Description

High-throughput rRNA depletion reagents for up to 1536 samples (96 samples per reaction pool); designed for DRUG-Seq and high-throughput screening applications with >99% rRNA depletion per sample.

11Custom Guide RNA Design Service
CategoryCustom Services
Description

Customized CRISPRclean reagent design service for removing unwanted DNA or RNA fragments from NGS libraries; experience with plant genomes (maize, wheat), mammalian genomes, and tissue-specific RNA-seq panels; supports automation-friendly formats.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-03-27
Description

Non-exclusive CRISPR/Cas9 license agreement providing Jumpcode access to CRISPR gene editing technology to enhance next-generation sequencing capabilities.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Part of Ginkgo Technology Network consortium. Jumpcode contributing depletion technology to €24M EU4Health grant program for developing rapid, point-of-care sequencing-based test for respiratory pathogens.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2024-02-28
Description

Jumpcode joined Ginkgo's Technology Network as an inaugural partner providing integrated R&D capabilities for biosecurity and cell programming applications.

Strategic tierFlagshipTypeTechnology or Integration
Description

10x Genomics Compatible Products Partner. Jumpcode Single Cell RNA Boost Kit validated with 10x Genomics Chromium Single Cell 3' and 5' Gene Expression platforms, Visium Spatial, and multiome workflows.

Strategic tierFlagshipTypeTechnology or Integration
Description

PacBio Compatible Partner. Combination of Jumpcode Single Cell RNA Boost Kit and PacBio MAS-Seq for 10x Single Cell 3' kit maximizes usable single cell RNA sequencing data.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration and co-marketing partnership validating Jumpcode's CRISPRclean technology on Element's AVITI System. Demonstrated improved data quality and cost savings across genomic applications.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership for BD Rhapsody Whole Transcriptome Analysis integration. DepleteX Mito DNA Depletion Kit compatible with BD Rhapsody WTA workflow for improved single cell data in challenging samples.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Research collaboration for COVID-19 genomic sequencing and pandemic preparedness. Joint publication in Cell Reports Methods demonstrating CRISPR-NGS approach for universal infectious disease testing.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Global distributor for Jumpcode's range of programmable endonuclease enzymes and ribodepletion solutions.

10Scientific Advisory Board
Strategic tierCoreTypeOthers
Description

Board includes Gene Yeo (UCSD), Shawn Levy (Cellanome), Stan Nelson (UCLA), Nik Schork (HonorHealth), Andrew Su (Scripps). Provides scientific guidance and industry expertise.

jumpcodegenomics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lexogen offers RiboCop, SIRV, and QuantSeq ribodepletion and library prep kits that compete head-to-head with Jumpcode's CRISPRclean RNA Prep and DepleteX kits in RNA-seq workflows.

TypeBroad incumbent
Description

QIAGEN's QIAseq FastSelect rRNA and globin removal kits are direct competitive reagents to Jumpcode's depletion panels, distributed as part of a much broader life sciences tools portfolio.

TypeBroad incumbent
Description

Illumina's Ribo-Zero Plus and TruSeq ribodepletion products compete with Jumpcode in NGS sample prep, while Illumina's sequencing platforms also serve as upstream/downstream context for Jumpcode's depletion kits.

TypeDirect peer
Description

New England Biolabs offers NEBNext rRNA Depletion Kits and a broad NGS sample prep portfolio that directly competes with Jumpcode's CRISPRclean and DepleteX kits for ribodepletion and library prep workflows.

TypeOthers
Description

Ginkgo Bioworks is a strategic co-development partner on the €24M EU4Health POC respiratory test and Ginkgo Technology Network member; while not a reagent competitor, it represents both a partnership channel and a benchmark for synthetic biology-driven platform plays.

TypeBroad incumbent
Description

Revvity (formerly PerkinElmer) is both a global distributor of Jumpcode's ribodepletion reagents and a broader competitor in NGS sample prep and diagnostics, illustrating the dual channel/competitive relationship.

TypeBroad incumbent
Description

Bio-Rad offers the SEQuoia Complete Library Prep Kit with ribodepletion for NGS workflows and serves comparable academic and biotech customers, though as part of a much broader life sciences portfolio.

TypeBroad incumbent
Description

IDT offers rRNA depletion and library prep products under the xGen brand and serves overlapping NGS sample prep customers; it also provides custom oligo services that compete with Jumpcode's Custom Guide RNA Design.

TypeOthers
Description

10x Genomics is a Compatible Partner that validates Jumpcode's Single Cell RNA Boost Kit on Chromium and Visium platforms, but is also a strategic sequencing platform provider whose roadmap decisions shape Jumpcode's addressable market.

TypeBroad incumbent
Description

Roche's KAPA RNA HyperPrep and ribodepletion reagents are widely adopted NGS sample prep products that compete with Jumpcode in research and clinical sequencing workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jumpcode Genomics

Genomics Sample Preparation Reagentsjumpcodegenomics.com

Jumpcode Genomics develops CRISPR-Cas9 based DepleteX™ and CRISPRclean™ reagent kits that remove uninformative sequences (rRNA, mitochondrial DNA, host DNA) from next-generation sequencing libraries, serving academic, biotech, and public-health researchers globally.

What Jumpcode Genomics does

Jumpcode Genomics is a privately held life-sciences tools company, founded in 2016 and headquartered in San Diego, California, that develops and sells CRISPR-Cas9 based nucleic-acid depletion reagents branded as DepleteX™ and CRISPRclean™. The company's core technology uses pools of designed guide RNAs to cleave abundant, uninformative sequences — ribosomal RNA, mitochondrial DNA/RNA, globin, high-expressing housekeeping transcripts, and host DNA in microbiome samples — in next-generation sequencing (NGS) libraries prior to sequencing, redistributing read capacity toward biologically relevant molecules. The product portfolio spans core kits (Single Cell RNA Boost, Mitochondrial DNA Depletion, Human DNA Depletion, Stranded Total RNA Prep with rRNA depletion for human/mouse/rat plus 212 bacterial species), add-on panels (Nasopharyngeal Microbial RNA Boost, High Expressing RNA, Globin, Insulin), bulk-format reagents for high-throughput screening, and a Custom Guide RNA Design service. Validated integrations with 10x Genomics, PacBio, BD Rhapsody, Element AVITI, and Parse Evercode platforms position the kits as an upstream depletion step in established single-cell and bulk sequencing workflows.

The company sells primarily through direct sales with quote-based pricing (kit-level price points disclosed at roughly $3,000–$7,680 for catalog SKUs), supplemented by a global distribution network anchored by Revvity and regional partners covering DACH, Japan, Korea, France, and ANZ. Customers span academic and translational research institutions (University of Oxford, University of Verona, Polytechnic University of Marche, TGen) and early commercial users (ImYoo), with no disclosed large-pharma reference accounts. Go-to-market emphasizes scientific publications (Genome Research, Cell Reports Methods, bioRxiv), customer stories, technical webinars, and presence at genomics conferences (PAG, ASHG, ASM Microbe, ABRF). Strategic positioning has expanded beyond research tools into public-health and biodefense applications via the BARDA DRIVe partnership and the €24 million EU4Health grant consortium with Ginkgo Bioworks and TGen.

Jumpcode has raised approximately $23.5 million in total disclosed equity funding, including a $21 million Series B in January 2021 co-led by Baird Capital and Arboretum Ventures with LYZZ Capital. The company operates with 11–50 employees and is led by CEO Yaron Hakak (ex-Illumina, Affymetrix, Arena Pharmaceuticals), CFO Brandon Poe (ex-Illumina, Genome Medical), and Chief Scientist Stanley Nelson (UCLA), with board representation from operating partner Frank Witney (former Affymetrix and Dionex CEO). Revenue is not publicly disclosed, and the company has not announced a Series C or IPO as of 2025.

Jumpcode Genomics firmographics

Firmographics
Name
Jumpcode Genomics
Legal name
Jumpcode Genomics, Inc.
Website
https://jumpcodegenomics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Jumpcode Genomics develops CRISPR-Cas9 based DepleteX™ and CRISPRclean™ reagent kits that remove uninformative sequences (rRNA, mitochondrial DNA, host DNA) from next-generation sequencing libraries, serving academic, biotech, and public-health researchers globally.
Ownership category
akta.pro rank

Jumpcode Genomics industry classification

Industry
Product category
Genomics Sample Preparation Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • NGS depletion kits
  • CRISPR-Cas9 reagents
  • Ribodepletion solutions
  • Single cell RNA boost
  • Microbiome sequencing tools

Where Jumpcode Genomics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Jumpcode Genomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Research Kits and Reagents: Sale of DepleteX™ and CRISPRclean™ reagent kits for NGS library preparation and depletion. Products include single cell RNA boost kits, ribodepletion kits, mitochondrial DNA depletion kits, human DNA depletion kits, and bulk ribodepletion reagents. Revenue generated through direct sales and distributor network.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goDepleteX™ Human DNA Depletion Kit (KIT2020) - Early Access
Unit PricingPay-as-you-goCRISPRClean™ Bulk Ribodepletion Reagents (Human, Mouse, Rat) - KIT1026
Unit PricingPay-as-you-goCRISPRclean™ Plus Stranded Total RNA Prep - KIT1016
Unit PricingPay-as-you-goDepleteX™ Single Cell RNA Boost Kit - KIT1037

Go-to-market motion1 record

Distribution channels7 records

Marketing channels6 records

Jumpcode Genomics product offering

Product offering

Core offering

Jumpcode Genomics develops and sells CRISPR-Cas9 based nucleic acid depletion kits (branded DepleteX™ and CRISPRclean™) that remove abundant, uninformative sequences — such as ribosomal RNA, mitochondrial DNA, globin transcripts, and high-expressing housekeeping genes — from next-generation sequencing (NGS) libraries prior to sequencing. The portfolio includes single cell RNA boost kits, ribodepletion kits, mitochondrial and human DNA depletion kits, tissue-specific RNA depletion panels, bulk ribodepletion reagents, and custom guide RNA design services for life sciences researchers.

Product overview

Jumpcode Genomics offers a CRISPR-Cas9 based technology platform called DepleteX™ / CRISPRclean™ for removing unwanted sequences from NGS libraries prior to sequencing. The product portfolio consists of: (1) Core depletion kits including DepleteX™ Single Cell RNA Boost Kit (KIT1037), DepleteX™ Mitochondrial DNA Depletion Kit (KIT2002), DepleteX™ Human DNA Depletion Kit (KIT2020), CRISPRclean™ Plus Stranded Total RNA Prep with rRNA Depletion (KIT1016), and CRISPRclean™ Stranded Total RNA Prep with rRNA Depletion (KIT1014); (2) Add-on depletion panels including DepleteX™ Nasopharyngeal Microbial RNA Boost (KIT1039), DepleteX™ High Expressing RNA Depletion Kit (KIT1020), DepleteX™ Globin Depletion Kit (KIT1024), DepleteX™ RNA Depletion Panel/Insulin (KIT1025), and Bulk Ribodepletion Reagents (KIT1026); (3) Custom Guide RNA Design service for customized depletion panels. These products work together as an integrated workflow—core kits provide foundational depletion capabilities while add-on panels offer targeted depletion for specific tissues or applications, all utilizing the patented CRISPR-Cas9 mediated depletion technology to remove abundant uninformative sequences and redistribute sequencing reads to biologically relevant molecules.

Differentiator

Problem solved

Functional benefit

Brands

  • DepleteX™: Programmable endonuclease technology platform for NGS depletion using CRISPR-Cas9 to remove uninformative sequences.
  • CRISPRclean™

Products and services

  • DepleteX™ Single Cell RNA Boost Kit A CRISPR-Cas9 based kit that removes ribosomal, mitochondrial, non-variable gene fragments, and other uninformative reads before single cell RNA sequencing, redistributing ~50% of sequencing clusters to informative reads. Validated for short and long read sequencing with 10x Genomics, PacBio, and BD Rhapsody platforms; 24 samples per kit.
  • DepleteX™ Mitochondrial DNA Depletion Kit CRISPR-based depletion kit that removes mitochondrial DNA or RNA from human-derived tissue samples with high mitochondrial content, redirecting sequencing reads to biologically valuable information.
  • DepleteX™ Human DNA Depletion Kit CRISPR-based depletion kit that removes human DNA from microbiome samples with high human contamination, achieving a 16-fold increase in bacterial reads and unbiased preservation of microbial community composition.
  • CRISPRclean™ Plus Stranded Total RNA Prep with rRNA Depletion Stranded total RNA library prep with integrated ribosomal RNA depletion targeting 200+ bacteria species in addition to human, mouse, and rat rRNA. Achieves >80% depletion of eukaryotic and bacterial rRNA, suitable for complex samples containing mixtures of eukaryotic and bacterial cells; 24 samples per kit.
  • CRISPRclean™ Stranded Total RNA Prep with rRNA Depletion (Human, Mouse, Rat) Specific, unbiased rRNA depletion and library prep for RNA-seq targeting human 5S, 5.8S, 18S, 28S, 45S precursor, and mitochondrial rRNA genes; provides >98% strand specificity and high-quality representation of transcripts.
  • DepleteX™ Nasopharyngeal Microbial RNA Boost Removes abundant human RNA from nasopharyngeal samples to boost discovery of novel microbes and pathogens; enables pathogen detection at Cq values up to 30 with 4 million reads.
  • DepleteX™ Rare Transcript Boost Kit (High Expressing RNA Depletion Kit) Broad RNA depletion panel removing the ~4,450 highest expressing transcripts from poly-A selected RNA-Seq libraries derived from fibroblasts and whole blood, reassigning ~70% of sequencing reads to low-expressing biologically relevant transcripts and providing ~5-fold increased coverage of lower expressing transcripts.
  • DepleteX™ Globin Depletion Kit Removes four highly expressed human globin transcripts (HBA1, HBA2, HBB, HBD) from RNA-seq libraries, achieving >99% depletion and redistributing sequencing clusters to biologically relevant transcripts for maximized UMI and gene sensitivity.
  • DepleteX™ Insulin Depletion Kit Tissue-specific depletion panel removing highest expressing insulin transcripts from pancreatic tissue samples, reassigning sequencing reads to lower expressing transcripts for increased coverage.
  • CRISPRclean™ Bulk Ribodepletion Reagents (Human, Mouse, Rat) High-throughput rRNA depletion reagents for up to 1536 samples (96 samples per reaction pool); designed for DRUG-Seq and high-throughput screening applications with >99% rRNA depletion per sample.
  • Custom Guide RNA Design Service Customized CRISPRclean reagent design service for removing unwanted DNA or RNA fragments from NGS libraries; experience with plant genomes (maize, wheat), mammalian genomes, and tissue-specific RNA-seq panels; supports automation-friendly formats.

Quantifiable outcome

  • ~50% boost in reads useful for secondary analysis in single cell RNA-seq
  • +6 more outcomes

Companies that use Jumpcode Genomics

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Jumpcode Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Jumpcode Genomics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and flagship.

  • ERS GenomicscoreOEM/ Whitelabel/ Licensing Partner · 27 March 2025Non-exclusive CRISPR/Cas9 license agreement providing Jumpcode access to CRISPR gene editing technology to enhance next-generation sequencing capabilities.
  • Ginkgo BioworksflagshipStrategic or Co-development Partner · 1 January 2025Part of Ginkgo Technology Network consortium. Jumpcode contributing depletion technology to €24M EU4Health grant program for developing rapid, point-of-care sequencing-based test for respiratory pathogens.
  • Ginkgo Bioworks Technology NetworkcoreGTM or Marketing Partner · 28 February 2024Jumpcode joined Ginkgo's Technology Network as an inaugural partner providing integrated R&D capabilities for biosecurity and cell programming applications.
  • 10x GenomicsflagshipTechnology or Integration10x Genomics Compatible Products Partner. Jumpcode Single Cell RNA Boost Kit validated with 10x Genomics Chromium Single Cell 3' and 5' Gene Expression platforms, Visium Spatial, and multiome workflows.
  • PacBioflagshipTechnology or IntegrationPacBio Compatible Partner. Combination of Jumpcode Single Cell RNA Boost Kit and PacBio MAS-Seq for 10x Single Cell 3' kit maximizes usable single cell RNA sequencing data.
  • Element BiosciencescoreTechnology or IntegrationCollaboration and co-marketing partnership validating Jumpcode's CRISPRclean technology on Element's AVITI System. Demonstrated improved data quality and cost savings across genomic applications.
  • BD (Becton, Dickinson and Company)coreTechnology or IntegrationPartnership for BD Rhapsody Whole Transcriptome Analysis integration. DepleteX Mito DNA Depletion Kit compatible with BD Rhapsody WTA workflow for improved single cell data in challenging samples.
  • Translational Genomics Research Institute (TGen)flagshipStrategic or Co-development PartnerResearch collaboration for COVID-19 genomic sequencing and pandemic preparedness. Joint publication in Cell Reports Methods demonstrating CRISPR-NGS approach for universal infectious disease testing.
  • RevvitycoreChannel Partner/ Reseller/ DistributorGlobal distributor for Jumpcode's range of programmable endonuclease enzymes and ribodepletion solutions.
  • Scientific Advisory BoardcoreOthersBoard includes Gene Yeo (UCSD), Shawn Levy (Cellanome), Stan Nelson (UCLA), Nik Schork (HonorHealth), Andrew Su (Scripps). Provides scientific guidance and industry expertise.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Jumpcode Genomics competitors and assessment

Company assessment

Direct peers

  • Lexogen: Lexogen offers RiboCop, SIRV, and QuantSeq ribodepletion and library prep kits that compete head-to-head with Jumpcode's CRISPRclean RNA Prep and DepleteX kits in RNA-seq workflows.
  • New England Biolabs: New England Biolabs offers NEBNext rRNA Depletion Kits and a broad NGS sample prep portfolio that directly competes with Jumpcode's CRISPRclean and DepleteX kits for ribodepletion and library prep workflows.

Broad incumbents

  • QIAGEN: QIAGEN's QIAseq FastSelect rRNA and globin removal kits are direct competitive reagents to Jumpcode's depletion panels, distributed as part of a much broader life sciences tools portfolio.
  • Illumina: Illumina's Ribo-Zero Plus and TruSeq ribodepletion products compete with Jumpcode in NGS sample prep, while Illumina's sequencing platforms also serve as upstream/downstream context for Jumpcode's depletion kits.
  • PerkinElmer (Revvity): Revvity (formerly PerkinElmer) is both a global distributor of Jumpcode's ribodepletion reagents and a broader competitor in NGS sample prep and diagnostics, illustrating the dual channel/competitive relationship.
  • Bio-Rad Laboratories: Bio-Rad offers the SEQuoia Complete Library Prep Kit with ribodepletion for NGS workflows and serves comparable academic and biotech customers, though as part of a much broader life sciences portfolio.
  • Integrated DNA Technologies (IDT): IDT offers rRNA depletion and library prep products under the xGen brand and serves overlapping NGS sample prep customers; it also provides custom oligo services that compete with Jumpcode's Custom Guide RNA Design.
  • Roche (KAPA Biosystems): Roche's KAPA RNA HyperPrep and ribodepletion reagents are widely adopted NGS sample prep products that compete with Jumpcode in research and clinical sequencing workflows.

Others

  • Ginkgo Bioworks: Ginkgo Bioworks is a strategic co-development partner on the €24M EU4Health POC respiratory test and Ginkgo Technology Network member; while not a reagent competitor, it represents both a partnership channel and a benchmark for synthetic biology-driven platform plays.
  • 10x Genomics: 10x Genomics is a Compatible Partner that validates Jumpcode's Single Cell RNA Boost Kit on Chromium and Visium platforms, but is also a strategic sequencing platform provider whose roadmap decisions shape Jumpcode's addressable market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Jumpcode Genomics social profiles

Digital presence

Jumpcode Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jumpcode Genomics leadership team

Management profile

Number of profiles

Profiles17 records

Jumpcode Genomics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jumpcode Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jumpcode Genomics

What does Jumpcode Genomics do?

Jumpcode Genomics develops and sells CRISPR-Cas9 based nucleic acid depletion kits (branded DepleteX™ and CRISPRclean™) that remove abundant, uninformative sequences — such as ribosomal RNA, mitochondrial DNA, globin transcripts, and high-expressing housekeeping genes — from next-generation sequencing (NGS) libraries prior to sequencing. The portfolio includes single cell RNA boost kits, ribodepletion kits, mitochondrial and human DNA depletion kits, tissue-specific RNA depletion panels, bulk ribodepletion reagents, and custom guide RNA design services for life sciences researchers.

Is Jumpcode Genomics a public or private company?

Jumpcode Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Jumpcode Genomics founded?

Jumpcode Genomics was founded in 2016. It employs 1 to 10 people.

Where is Jumpcode Genomics based?

Jumpcode Genomics is headquartered in San Diego, United States, in the North America region.

How does Jumpcode Genomics make money?

One revenue line is on record: research Kits and Reagents.

Who are Jumpcode Genomics's main competitors?

Direct peers on record are Lexogen and New England Biolabs. Broad incumbents are QIAGEN, Illumina, PerkinElmer (Revvity), Bio-Rad Laboratories, Integrated DNA Technologies (IDT) and Roche (KAPA Biosystems). Others are Ginkgo Bioworks and 10x Genomics.

Does Jumpcode Genomics have an API?

No public API is recorded for Jumpcode Genomics.

What industry is Jumpcode Genomics in?

Jumpcode Genomics's product category is Genomics Sample Preparation Reagents. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 325414 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMutation Detection Kits in Genome Editing Market - Competitive Benchmarking and Dashboard Report 2025The global market for mutation detection kits in genome editing is projected to grow from $1.14 billion in 2025 to $1.86 billion by 2029, driven by increasing prevalence of genetic disorders and rising demand for precise diagnostic tools. In April 2024, Bio-Rad Laboratories launched the ddPLEX ESR1 Mutation Detection Kit, an ultrasensitive multiplexed digital PCR assay capable of detecting seven ESR1 mutations at a variant allele fraction sensitivity of 0.01%. In March 2025, ERS Genomics partnered with Jumpcode Genomics to leverage CRISPR/Cas9 patent technology for advancing next-generation sequencing capabilities across research and diagnostic applications.PR NewswireNew Research Demonstrates Potential of Jumpcode Genomics Depletion Technology to Improve Pandemic ResponseJumpcode Genomics and the Translational Genomics Research Institute (TGen) announced study results published in Cell Reports Methods demonstrating the potential of their CRISPR-enhanced depletion technology for pandemic response. The research indicates that this pathogen-agnostic next-generation sequencing method can detect SARS-CoV-2 with sensitivity comparable to RT-qPCR while also identifying variant strains and co-infecting pathogens. These findings suggest the technology could overcome previous limitations of time-consuming workflows and infrastructure needs, offering a more flexible tool for future infectious disease testing.BioSpaceJumpcode Genomics Joins 10x Genomics’ Compatible Partner Program (CPP)Jumpcode Genomics announced a partnership with 10x Genomics to integrate its Single Cell RNA Boost Kit with the 10x Genomics Chromium Single Cell Gene Expression platform. This collaboration allows scientists to improve the sensitivity of single-cell RNA sequencing by reducing uninformative sequences and increasing usable data. The integration is part of 10x Genomics' Compatible Partner Program, validating Jumpcode's CRISPRclean technology for use within established workflows.PR NewswireJumpcode Genomics Joins 10x Genomics' Compatible Partner Program (CPP)Jumpcode Genomics joined 10x Genomics' Compatible Partner Program, integrating its Single Cell RNA Boost Kit with the Chromium Single Cell Gene Expression platform. The kit uses CRISPRclean technology to degrade uninformative sequences, redistributing 50% of sequencing clusters to biologically relevant transcripts. The partnership aims to improve sensitivity and data yield for single-cell RNA sequencing.GenomeWebPeople in the News: New Appointments at Jumpcode Genomics, Quantum-Si, Quanterix, SeqWell, MoreJumpcode Genomics, Quantum-Si, Quanterix, and SeqWell have announced new executive appointments and board additions to strengthen their leadership teams. Jumpcode Genomics appointed three vice presidents for R&D, marketing, and sales; Quantum-Si named a chief medical advisor from Harvard-affiliated institutions; Quanterix added an executive with prior Pfizer experience to its board; and SeqWell installed a new president and CEO with extensive industry background.GenomeWebJumpcode Genomics: Jon Armstrong, Kerri McWeeny, Jonathan BellJumpcode Genomics has appointed Jon Armstrong, Kerri McWeeny, and Jonathan Bell to the roles of vice president of research and development, vice president of marketing, and vice president of sales, respectively. The new executives bring prior experience from industry peers including Cofactor Genomics, Illumina, Affymetrix, and Bio-Rad. This leadership expansion signals organizational growth for the genomics company.FinSMEsJumpcode Genomics Raises $21M in Series B FundingJumpcode Genomics raised $21M in Series B funding co-led by Baird Capital and Arboretum Ventures, with participation from LYZZ Capital. The San Diego-based genome technology company, founded in 2016, provides CRISPRclean technology for next-generation sequencing. Frank Witney joined the board in conjunction with the funding.San Diego Business JournalJumpcode Secures $21MJumpcode Genomics has secured $21 million in Series B funding, co-led by Baird Capital and Arboretum Ventures with participation from LYZZ Capital. The company intends to use the capital to accelerate the commercialization of its CRISPRclean technology, expand into new market segments, and grow its team.GenomeWebJumpCode Genomics Raises $21M in Series B Financing RoundJumpCode Genomics announced on January 12, 2021, that it raised $21 million in a Series B financing round. The company is based in New York and operates within the gene editing and genomic technologies sector. This funding supports the company's ongoing development of its proprietary technologies.